ZTS - Zoetis Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
102.03
+0.06 (+0.05%)
As of 10:17AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close101.97
Open101.89
Bid101.83 x 4000
Ask101.89 x 800
Day's Range101.60 - 102.24
52 Week Range77.00 - 103.33
Volume276,987
Avg. Volume2,285,938
Market Cap48.885B
Beta (3Y Monthly)0.65
PE Ratio (TTM)34.82
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.66 (0.65%)
Ex-Dividend Date2019-04-17
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zoetis CEO on health care for animals: Brazil is growing 'very fast'
    CNBC Videos2 months ago

    Zoetis CEO on health care for animals: Brazil is growing 'very fast'

    Jim Cramer sits down with Zoetis CEO Juan Ramos Alaix to discuss how parents pay for their pets' health care and a future product launch.

  • Zacks.com featured expert Kevin Matras highlights: Cadence Design System, CSX, Celanese and Zoetis
    Zacksyesterday

    Zacks.com featured expert Kevin Matras highlights: Cadence Design System, CSX, Celanese and Zoetis

    Zacks.com featured expert Kevin Matras highlights: Cadence Design System, CSX, Celanese and Zoetis

  • 4 GARP Stocks to Scoop Up for Maximum Returns
    Zacks2 days ago

    4 GARP Stocks to Scoop Up for Maximum Returns

    If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

  • JAZZ vs. ZTS: Which Stock Is the Better Value Option?
    Zacks8 days ago

    JAZZ vs. ZTS: Which Stock Is the Better Value Option?

    JAZZ vs. ZTS: Which Stock Is the Better Value Option?

  • Which Pharmaceutical Stocks Are Outperforming All Other Stocks?
    Investor's Business Daily20 days ago

    Which Pharmaceutical Stocks Are Outperforming All Other Stocks?

    The best pharmaceutical stocks to buy have commonalities: Strong Composite Ratings and Relative Strength Ratings.

  • Markit22 days ago

    See what the IHS Markit Score report has to say about Zoetis Inc.

    Zoetis Inc NYSE:ZTSView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ZTS are favorable, with net inflows of $10.94 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Zoetis Inc. (NYSE:ZTS): Are Analysts Bullish?
    Simply Wall St.22 days ago

    Zoetis Inc. (NYSE:ZTS): Are Analysts Bullish?

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The latest earnings announcement Zoetis Inc. (NYSE:ZTS) released in December 2018 confirmed...

  • Benzinga25 days ago

    Barron's Picks And Pans: DowDuPont, Wells Fargo, Zoetis And More

    This weekend's Barron's cover story offers a head-to-head matchup of the two leading U.S. telecoms. Other featured articles examine prospects for an industrial giant undergoing a colossal restructuring ...

  • Barrons.com26 days ago

    The Truth About Cats: They Are a Hot Growth Area in Animal Health

    Illnesses in cats are considered harder to diagnose than those in dogs. And try getting one to take a pill.

  • Barrons.com26 days ago

    There Are Animal Spirits in This Health-Care Business

    People are spending more on their cats and dogs, while the livestock business continues to grow. Still, opportunities are limited.

  • Were Hedge Funds Right About Buying Zoetis Inc (ZTS)?
    Insider Monkey27 days ago

    Were Hedge Funds Right About Buying Zoetis Inc (ZTS)?

    At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we've gathered as a result gives us access to a wealth of collective knowledge based on these firms' portfolio holdings as of December 31. In this […]

  • Why Is Zoetis (ZTS) Up 3.9% Since Last Earnings Report?
    Zackslast month

    Why Is Zoetis (ZTS) Up 3.9% Since Last Earnings Report?

    Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GuruFocus.com2 months ago

    Zoetis Inc (ZTS) CEO Juan Ramon Alaix Sold $29.4 million of Shares

    CEO of Zoetis Inc (NYSE:ZTS) Juan Ramon Alaix sold 312,109 shares of ZTS on 02/28/2019 at an average price of $94.06 a share.

  • 5 Pharmaceutical Stocks With Big Moats and Bridges
    Kiplinger2 months ago

    5 Pharmaceutical Stocks With Big Moats and Bridges

    Pharmaceuticals are a tricky business. Public policy, science, R&D;, global growth and regulation all play a role, sometimes outsize, in the success of pharmaceutical stocks.But some Big Pharma companies and a few other industry firms have managed these and other factors better than others. And along the way, they have built up a considerable "moat" - some sort of considerable competitive advantage - around profitable businesses. Some of these same companies are building bridges to further profitability via deep drug pipelines, innovative new treatments and transformative acquisitions.Here's a deeper look into five pharmaceutical stocks that have compelling moats, bridges or both. These advantages make them more likely to provide stable growth over the long term. SEE ALSO: The Best Health-Care Stocks to Buy for 2019

  • Don’t Sell Zoetis Inc. (NYSE:ZTS) Before You Read This
    Simply Wall St.2 months ago

    Don’t Sell Zoetis Inc. (NYSE:ZTS) Before You Read This

    This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at Zoetis Inc.'s (NYSE:ZTS) P/E ratio and reflect onRead More...

  • What Are the Major Risks Affecting Elanco Animal Health?
    Market Realist2 months ago

    What Are the Major Risks Affecting Elanco Animal Health?

    Elanco or Zoetis: Which Is a Better Animal Health Pick in February?(Continued from Prior Part)Underperforming businesses In its fourth-quarter earnings conference call, Elanco Animal Health (ELAN) reported a 4% YoY drop in sales driven by a 9%

  • Here Are Zoetis’s Key Revenue Drivers in Fiscal 2019
    Market Realist2 months ago

    Here Are Zoetis’s Key Revenue Drivers in Fiscal 2019

    Elanco or Zoetis: Which Is a Better Animal Health Pick in February?(Continued from Prior Part)Revenue performance in fiscal 2018In fiscal 2018, Zoetis (ZTS) reported revenues of $5.83 billion, a YoY rise of 10.0% on a reported basis and 8% on an

  • ELAN or ZTS: Who Is Controlling Expenses Better?
    Market Realist2 months ago

    ELAN or ZTS: Who Is Controlling Expenses Better?

    Elanco or Zoetis: Which Is a Better Animal Health Pick in February?(Continued from Prior Part)Expense guidance for fiscal 2019In its mid-December 2018 guidance call, Elanco Animal Health (ELAN) highlighted various restructuring activities aimed at

  • ELAN or ZTS: Who Is Expected to Report Faster EPS Growth?
    Market Realist2 months ago

    ELAN or ZTS: Who Is Expected to Report Faster EPS Growth?

    Elanco or Zoetis: Which Is a Better Animal Health Pick in February?(Continued from Prior Part)EPS guidance for fiscal 2019In its fourth-quarter earnings investor presentation, Elanco Animal Health (ELAN) reiterated its fiscal 2019 GAAP and non-GAAP

  • 3 Stocks to Buy and Hold for the Next 50 Years
    Motley Fool2 months ago

    3 Stocks to Buy and Hold for the Next 50 Years

    Microsoft, Boeing, and Zoetis could all be great "forever" investments.

  • What Analysts Are Recommending for ELAN and ZTS in February
    Market Realist2 months ago

    What Analysts Are Recommending for ELAN and ZTS in February

    Elanco or Zoetis: Which Is a Better Animal Health Pick in February?Stock price movementsOn February 19, Elanco Animal Health (ELAN) closed at $29.16, 1.49% lower than its previous closing price, 4.14% higher than its 52-week low of $28.00, and

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ZTS earnings conference call or presentation 14-Feb-19 1:30pm GMT

    Q4 2018 Zoetis Inc Earnings Call

  • TheStreet.com2 months ago

    Zoetis Is in a Strong Uptrend So Don't Expect Much of a Dip to Buy It

    In his second "Executive Decision" segment of Mad Money Friday night, Jim Cramer sat down with Juan Ramon Alaix, CEO of Zoetis Inc. ZTS is an animal health company with shares that vaulted 9.8% last week after another strong quarter. Alaix added that Zoetis has effective treatments for a number of conditions, including ticks, fleas, heartworm and other parasites.

  • Moody's2 months ago

    Zoetis Inc. -- Moody's announces completion of a periodic review of ratings of Zoetis Inc.

    Announcement: Moody's announces completion of a periodic review of ratings of Zoetis Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Zoetis Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.